Some superficial fungal infections can cause systemic infections in people who are immunocompromised. Some subcutaneous fungal infections can invade into deeper structures, resulting in systemic disease. Candida albicans can live in people without producing symptoms, and is able to cause both mild candidiasis in healthy people and severe invasive candidiasis in those who cannot fight infection themselves. ICD-11 codes
ICD-11 codes include:

Superficial mycoses
Superficial mycoses include candidiasis in healthy people, common tinea of the skin, such as tinea of the body, groin, hands, feet and beard, and malassezia infections such as pityriasis versicolor. Subcutaneous
Subcutaneous fungal infections include sporotrichosis, chromoblastomycosis, and eumycetoma. Systemic
Systemic fungal infections include histoplasmosis, cryptococcosis, coccidioidomycosis, blastomycosis, mucormycosis, aspergillosis, pneumocystis pneumonia and systemic candidiasis.Systemic mycoses due to primary pathogens originate normally in the lungs and may spread to other organ systems. Organisms that cause systemic mycoses are inherently virulent.. Systemic mycoses due to opportunistic pathogens are infections of people with immune deficiencies who would otherwise not be infected. Examples of immunocompromised conditions include AIDS, alteration of normal flora by antibiotics, immunosuppressive therapy, and metastatic cancer. Examples of opportunistic mycoses include Candidiasis, Cryptococcosis and Aspergillosis. Signs and symptoms
Most common mild mycoses often present with a rash. Infections within the skin or under the skin may present with a lump and skin changes. Less common deeper fungal infections may present with pneumonia like symptoms or meningitis. Causes
Mycoses are caused by certain fungi; yeasts, molds and some fungi that can exist as both a mold and yeast.
The push to receive approval and begin production of Udenyca was due in large part to the quickly increasing cost of Neulasta, which has nearly tripled since its release in 2002.Pelmeg was approved for medical use in the European Union in November 2018.Fulphila was approved for medical use in the European Union in November 2018.Ziextenzo was approved for medical use in the European Union in November 2018.Fulphila was approved for medical use in Canada in December 2018.Grasustek was approved for medical use in the European Union in June 2019.Ziextenzo was approved for medical use in Australia in July 2019.Pelgraz was approved for medical use in Australia in August 2019.Lapelga and Neutropeg were approved for medical use in Australia in August 2019.Pegfilgrastim-bmez (Ziextenzo) was approved for medical use in the United States in November 2019.Cegfila was approved for medical use in the European Union in December 2019.Ziextenzo was approved for medical use in Canada in April 2020.Pegfilgrastim-apgf (Nyvepria) was approved for medical use in the United States in June 2020. Nyvepria was approved for medical use in the European Union in November 2020.Nyvepria was approved for medical use in Canada in October 2020.Stimufend was approved for medical use in the European Union in March 2022.Pegfilgrastim-pbbk (Fylnetra) was approved for medical use in the United States in May 2022.Pegfilgramstim-fpgk (Stimufend) was approved for medical use in the United States in September 2022. References
External links
"Pegfilgrastim". Drug Information Portal. U.S. National Library of Medicine. "FDA notifies Amgen of misbranding of its biological product Neulasta". U.S. Food and Drug Administration (FDA).